Moreover, the JQ1 and Milciclib combination both earlier and more effectively reduced the cell viability of the MYC-amplified Group 3 MB cell lines MB002, sD425, and D283 and the MYCN-amplified neuroblastoma cell line Kelly, as compared to the JQ1 and Palbociclib combination (Fig. 1e). The gene discussed is MYCN; the disease is neuroblastoma.